Survival in COPD patients after regular use of fluticasone propionate and salmeterol.
Marchand
E
E
D000280:Administration, Inhalation; D000420:Albuterol / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D000730:Androstadienes / Q000008:administration & dosage* / Q000009:adverse effects; D002423:Cause of Death; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D000068298:Fluticasone; D006801:Humans; D008297:Male; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D016032:Randomized Controlled Trials as Topic; D012129:Respiratory Function Tests; D018570:Risk Assessment; D000068299:Salmeterol Xinafoate; D012720:Severity of Illness Index; D016019:Survival Analysis
D000730:Androstadienes; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol